Temsirolimus in patients with advanced renal cell carcinoma: An overview

Advances in Therapy

Volumn 26, Issue 1, 2009, Pages 55-67

  Bhatia, Shailender ^a   Thompson, John A ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Kidney cancer; MTOR; Rapamycin; Renal cell carcinoma; Targeted therapies; Temsirolimus

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; DIPHENHYDRAMINE; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; PLACEBO; SORAFENIB; TEMSIROLIMUS;

ALLERGIC REACTION; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CYTOPENIA; DEPRESSION; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG MEGADOSE; DRUG METABOLISM; DRUG WITHDRAWAL; DYSPNEA; EDEMA; EUPHORIA; FATIGUE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; LEUKOPENIA; MAXIMUM PLASMA CONCENTRATION; MUCOSA INFLAMMATION; NAUSEA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHARMACOLOGICAL BLOCKING; PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY FAILURE; LIVER FAILURE; LIVER NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; SIROLIMUS;

EID: 73449084100     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-008-0138-3     Document Type: Review

References (49)

1. D.M. Parkin F. Bray J. Ferlay P. Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin. 55 74 108 15761078 10.3322/canjclin.55.2.74
2. R.J. Motzer N.H. Bander D.M. Nanus 1996 Renal-cell carcinoma N Engl J Med. 335 865 875 8778606 10.1056/NEJM199609193351207 1:STN:280: DyaK28zlslajtA%3D%3D (Pubitemid 26304070)
3. R.J. Motzer M. Mazumdar J. Bacik W. Berg A. Amsterdam J. Ferrara 1999 Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol. 17 2530 2540 10561319 1:STN:280:DC%2BD3c%2FjtVSnug%3D%3D
4. R.I. Fisher S.A. Rosenberg G. Fyfe 2000 Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma Cancer J Sci Am. 6 suppl1. S55 S57 10685660
5. R.J. Motzer B.A. Murphy J. Bacik 2000 Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma J Clin Oncol. 18 2972 2980 10944130 1:CAS:528: DC%2BD3cXmsFSktbc%3D
6. D.F. McDermott M.M. Regan J.I. Clark 2005 Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma J Clin Oncol. 23 133 141 15625368 10.1200/JCO.2005.03.206 1:CAS:528:DC%2BD2MXpslaktw%3D%3D (Pubitemid 41702632)
7. S. Negrier B. Escudier C. Lasset 1998 Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie N Engl J Med. 338 1272 1278 9562581 10.1056/NEJM199804303381805 1:CAS:528:DyaK1cXivF2qt74%3D (Pubitemid 28216581)
8. B. Escudier T. Eisen W.M. Stadler 2007 Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med. 356 125 134 17215530 10.1056/NEJMoa060655 1:CAS:528:DC%2BD2sXksVKitg%3D%3D (Pubitemid 46089673)
9. R.J. Motzer T.E. Hutson P. Tomczak 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med. 356 115 124 17215529 10.1056/NEJMoa065044 1:CAS:528:DC%2BD2sXksVGqsw%3D%3D (Pubitemid 46089672)
10. G. Hudes M. Carducci P. Tomczak 2007 Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med. 356 2271 2281 17538086 10.1056/NEJMoa066838 1:CAS:528:DC%2BD2sXmtVKkurs%3D (Pubitemid 46849157)
11. B.I. Rini S. Halabi J.E. Rosenberg 2008 Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 J Clin Oncol. 26 5422 5428 18936475 10.1200/JCO.2008.16. 9847 1:CAS:528:DC%2BD1MXhslClsA%3D%3D
12. B. Escudier A. Pluzanska P. Koralewski 2007 Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, doubleblind phase III trial Lancet 370 2103 2111 18156031 10.1016/S0140-6736(07) 61904-7 (Pubitemid 350296300)
13. R.J. Motzer B. Escudier S. Oudard 2008 Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 449 456 18653228 10.1016/S0140-6736(08)61039-9 1:CAS:528:DC%2BD1cXps1GmsLY%3D
14. S.N. Sehgal H. Baker C. Vezina 1975 Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization J Antibiot (Tokyo) 28 727 732 1:CAS:528:DyaE28Xis1eqsg%3D%3D
15. S.N. Sehgal K. Molnar-Kimber T.D. Ocain B.M. Weichman 1994 Rapamycin: a novel immunosuppressive macrolide Med Res Rev. 14 1 22 8309312 10.1002/med.2610140102 1:CAS:528:DyaK2cXhsFaktrY%3D
16. R. Cafferkey P.R. Young M.M. McLaughlin 1993 Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity Mol Cell Biol. 13 6012 6023 8413204 1:CAS:528:DyaK2cXksFCgsQ%3D%3D
17. J. Heitman N.R. Movva M.N. Hall 1991 Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast Science 253 905 909 1715094 10.1126/science.1715094 1:CAS:528:DyaK3MXlsl2hsr8%3D
18. E.J. Brown M.W. Albers T.B. Shin 1994 A mammalian protein targeted by G1-arresting rapamycin-receptor complex Nature 369 756 758 8008069 10.1038/369756a0 1:CAS:528:DyaK2cXlsFSiu74%3D (Pubitemid 24225367)
19. S. Hashemolhosseini Y. Nagamine S.J. Morley S. Desrivieres L. Mercep S. Ferrari 1998 Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability J Biol Chem. 273 14424 14429 9603954 10.1074/jbc.273.23.14424 1:CAS:528:DyaK1cXjs1Oqsrw%3D (Pubitemid 28319162)
20. L.M. Shantz A.E. Pegg 1994 Overproduction of ornithine decarboxylase caused by relief of translational repression is associated with neoplastic transformation Cancer Res. 54 2313 2316 8162572 1:CAS:528:DyaK2cXivFGntLc%3D
21. D.H. Kim D.D. Sarbassov S.M. Ali 2002 mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery Cell 110 163 175 12150925 10.1016/S0092-8674(02)00808-5 1:CAS:528:DC%2BD38XlvV2htr4%3D (Pubitemid 34876545)
22. M.A. Frias C.C. Thoreen J.D. Jaffe 2006 mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s Curr Biol. 16 1865 1870 16919458 10.1016/j.cub.2006.08.001 1:CAS:528:DC%2BD28Xps1Ons7s%3D (Pubitemid 44354144)
23. D.D. Sarbassov S.M. Ali D.H. Kim 2004 Rictor, a novel binding partner of mTOR, defines a rapamycininsensitive and raptor-independent pathway that regulates the cytoskeleton Curr Biol. 14 1296 1302 15268862 10.1016/j.cub.2004. 06.054 1:CAS:528:DC%2BD2cXmtVamsLs%3D (Pubitemid 38991819)
24. D.D. Sarbassov D.A. Guertin S.M. Ali D.M. Sabatini 2005 Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 307 1098 1101 15718470 10.1126/science.1106148 1:CAS:528:DC%2BD2MXhtlSrtbY%3D (Pubitemid 40262113)
25. D.D. Sarbassov S.M. Ali S. Sengupta 2006 Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB Mol Cell 22 159 168 16603397 10.1016/j.molcel.2006.03.029 1:CAS:528:DC%2BD28Xkt1GmtLo%3D
26. W.M. Linehan 2003 Molecular targeting of VHL gene pathway in clear cell kidney cancer J Urol. 170 593 594 12853837 10.1097/01.ju.0000077210.05543.ae
27. K. Kondo M. Yao M. Yoshida 2002 Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters Genes Chromosomes Cancer 34 58 68 11921283 10.1002/gcc.10054 1:CAS:528:DC%2BD38XjtFWju7s%3D (Pubitemid 34260597)
28. R.T. Abraham 2004 mTOR as a positive regulator of tumor cell responses to hypoxia Curr Top Microbiol Immunol. 279 299 319 14560965 1:CAS:528: DC%2BD3sXpt1Sku78%3D
29. W.M. Stadler 2005 Targeted agents for the treatment of advanced renal cell carcinoma Cancer 104 2323 2333 16240452 10.1002/cncr.21453 1:CAS:528:DC%2BD2MXhtlWgt7nF (Pubitemid 41691552)
30. L.C. Cantley B.G. Neel 1999 New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway Proc Natl Acad Sci U S A 96 4240 4245 10200246 10.1073/pnas.96.8.4240 1:CAS:528:DyaK1MXjs1ymtbg%3D (Pubitemid 29190320)
31. J.S. Lam J.T. Leppert R.A. Figlin A.S. Belldegrun 2005 Role of molecular markers in the diagnosis and therapy of renal cell carcinoma Urology 66 suppl. 1 9 16194700 10.1016/j.urology.2005.06.112 (Pubitemid 41356552)
32. M.S. Neshat I.K. Mellinghoff C. Tran 2001 Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR Proc Natl Acad Sci U S A 98 10314 10319 11504908 10.1073/pnas.171076798 1:CAS:528:DC%2BD3MXmvFWiurk%3D (Pubitemid 32803017)
33. K. Podsypanina R.T. Lee C. Politis 2001 An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice Proc Natl Acad Sci U S A 98 10320 10325 11504907 10.1073/pnas.171060098 1:CAS:528: DC%2BD3MXmvFWiurY%3D (Pubitemid 32803018)
34. Torisel (temsirolimus) package insert. Revised September 2008. Available at: www.wyeth.com/content/showlabelingasp?id=490. Accessed November 11, 2008.
35. M.B. Atkins M. Hidalgo W.M. Stadler 2004 Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma J Clin Oncol. 22 909 918 14990647 10.1200/JCO.2004.08.185 1:CAS:528: DC%2BD2cXpsVKisr0%3D (Pubitemid 41103603)
36. Boni J, Abbas R, Leister C, et al. Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus. Cancer Chemother Pharmacol. In press.
37. J.G. Kuhn S.M. Chang P.Y. Wen 2007 Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma Clin Cancer Res. 13 7401 7406 18094423 10.1158/1078-0432.CCR-07-0781 1:CAS:528:DC%2BD2sXhsVCktr3P
38. J. Boni C. Leister J. Burns M. Cincotta B. Hug L. Moore 2007 Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications J Clin Pharmacol. 47 1430 439 17913896 10.1177/0091270007306957 1:CAS:528:DC%2BD2sXhtlGru7jO (Pubitemid 47624594)
39. J.P. Boni C. Leister G. Bender 2005 Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer Clin Pharmacol Ther. 77 76 89 15637533 10.1016/j.clpt.2004.08.025 1:CAS:528:DC%2BD2MXks1Wq (Pubitemid 40075391)
40. G. Lunardi M.O. Vannozzi A. Armirotti M. Nicodemo M. Venturini L. Cavallini 2008 Temsirolimus in patients with renal cancer on hemodialysis J Clin Oncol. 26 5652 5653 18981458 10.1200/JCO.2008.19.3144
41. E. Raymond J. Alexandre S. Faivre 2004 Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer J Clin Oncol. 22 2336 2347 15136596 10.1200/JCO.2004.08.116 1:CAS:528:DC%2BD2cXpsVWltbc%3D (Pubitemid 41115390)
42. R.J. Motzer G.R. Hudes B.D. Curti 2007 Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma J Clin Oncol. 25 3958 3964 17761980 10.1200/JCO.2006.10.5916 1:CAS:528:DC%2BD2sXhtFanu73K (Pubitemid 47477274)
43. T.A. Huffman I. Mothe-Satney J.C. Lawrence Jr. 2002 Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin Proc Natl Acad Sci U S A 99 1047 1052 11792863 10.1073/pnas.022634399 1:CAS:528:DC%2BD38Xht1Wit7w%3D (Pubitemid 34106633)
44. C. Taha Z. Liu J. Jin H. Al-Hasani N. Sonenberg A. Klip 1999 Opposite translational control of GLUT1 and GLUT4 glucose transporter mRNAs in response to insulin. Role of mammalian target of rapamycin, protein kinase b, and phosphatidylinositol 3-kinase in GLUT1 mRNA translation J Biol Chem. 274 33085 33091 10551878 10.1074/jbc.274.46.33085 1:CAS:528:DyaK1MXntlygu7g%3D
45. I. Duran L.L. Siu A.M. Oza 2006 Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus Eur J Cancer 42 1875 1880 16806903 10.1016/j.ejca.2006.03.015 1:CAS:528:DC%2BD28XotFyltbw%3D (Pubitemid 44149096)
46. P.T. Pham P.C. Pham G.M. Danovitch 2004 Sirolimusassociated pulmonary toxicity Transplantation 77 1215 1220 15114088 10.1097/01.TP.0000118413.92211.B6 1:CAS:528:DC%2BD2cXksFOkuro%3D
47. Figlin RA, Hutson TE, Tomczak P, et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2008;26(suppl.). Abstract 5024.
48. Study comparing bevacizumab + temsirolimus vs bevacizumab + interferon-alfa in advanced renal cell carcinoma subjects. ClinicalTrials.gov web site. Available at: http://clinicaltrials.gov/ct2/show/NCT00631371?term= bevacizumab+temsirolimus+IFN&rank=1. Accessed December 2008.
49. Temsirolimus versus sorafenib as second-line therapy in patients with advanced RCC who have failed first-line sunitinib. ClinicalTrials.gov web site. Available at: http://clinicaltrials.gov/ct2/show/NC T00474786?term= temsirolimus+sorafenib+sunitini b&rank=1. Accessed December 2008.